Pharma Finds Its Way in AI
Executive SummaryEarly adopters of artificial intelligence are discovering how best to use it. Some of them are sharing lessons they have learned.
You may also be interested in...
Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.
New five-year deal shows convergence of big pharma and big tech continues – though both sectors are wary of hype surrounding AI and digital health.